Futura Medical plc (AIM: FUM), the pharmaceutical company developing innovative sexual health products, today announces that the Mexican Secretariat of Health has granted over the counter sale (“OTC”) Marketing Authorisation for Eroxon®, the Company’s breakthrough, topical gel formulation for the treatment of erectile dysfunction (“ED”). Read more…
Futura Medical plc (AIM: FUM), the pharmaceutical company developing innovative sexual health products, today announces that it has been granted allowance of its EU patent which will provide protection for MED3000 until 2040 in all European markets. In all other key ED markets including the US, the Company is continuing to prosecute patent applications to provide […]
Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology currently focused on sexual health, today announces that its breakthrough, topical gel formulation for the treatment of erectile dysfunction (ED), MED3000, under the brand name Eroxon®, is now […]
Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology, with a current focus on sexual health and pain, today announces that it will be presenting data on its lead product MED3000 for the treatment of erectile dysfunction (“ED”) at the European Society for […]
Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, announces that its partner, Cooper Consumer Health (“Cooper”) has initiated pre-launch activities ahead of the launch of MED3000 (Eroxon™), Futura’s breakthrough, topical gel formulation for the treatment of erectile […]
